Bio-Techne declares quarterly dividend contingent on Merck KGaA deal timing
Bio-Techne's board approved an $0.08 per share payout that will only go forward if the company's pending acquisition by Merck KGaA has not closed by the record date.
Bio-Techne Corporation announced on November 3, 2026 that its board of directors approved a dividend of $0.08 per share for the quarter ended September 30, 2026.1
The payment is tied to the status of a pending acquisition. The dividend is set to be paid on November 23, 2026 to shareholders of record as of November 13, 2026, but only if Bio-Techne's previously announced transaction with Merck KGaA, Darmstadt, Germany, has not closed by the close of business on that record date.1 The company noted that future dividends will be considered by the board on a quarterly basis, as applicable.1
Bio-Techne described itself as a global life sciences company providing tools and bioactive reagents for research and clinical diagnostic communities, which generated over $1.2 billion in net sales in fiscal 2026 and has approximately 3,000 employees worldwide.1
In its forward-looking statements section, the company flagged risks tied to the pending deal, including the timing of completion of the pending transaction, including whether it is completed on or before the dividend record date, the satisfaction of conditions such as shareholder and regulatory approvals, and the effect of the transaction's announcement or pendency on the business, operations and stock price.1
The filing was signed by Shane V. Bohnen, Senior Vice President, General Counsel and Secretary, dated November 3, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.